Medicilon(SH:688202)2025-04-29 11:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 267,091,301.60, representing a year-on-year increase of 2.92% compared to CNY 259,506,479.47 in the same period last year[4]. - The net profit attributable to shareholders of the listed company improved significantly, with a loss of CNY 14,546,830.68, a reduction in loss of CNY 23,008,900.74 compared to a loss of CNY 37,555,731.42 in the previous year[4][8]. - The net cash flow from operating activities was CNY 937,658.54, a substantial improvement from a negative cash flow of CNY 58,554,399.06 in the same period last year[4][8]. - The company achieved a comprehensive gross profit margin increase due to a 12.46% reduction in operating costs, contributing to the improved financial performance[8]. - The basic and diluted earnings per share were both -CNY 0.11, an improvement from -CNY 0.28 in the same period last year[4]. - The company reported a total comprehensive loss of CNY 14,571,328.68 for Q1 2025, compared to a loss of CNY 37,430,250.14 in Q1 2024[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,838,255,605.65, reflecting a slight increase of 0.53% from CNY 2,823,259,680.59 at the end of the previous year[5]. - Total liabilities increased to CNY 712,669,711.29 from CNY 683,102,457.55, reflecting a rise of 4.0%[15]. - The company's total equity decreased to CNY 2,125,585,894.36 from CNY 2,140,157,223.04, a decline of 0.7%[15]. Cash Flow - Cash flow from operating activities in Q1 2025 was CNY 235,153,156.60, compared to CNY 230,385,095.15 in Q1 2024, indicating a slight increase[20]. - The net cash flow from operating activities was 937,658.54, a significant improvement compared to a net outflow of -58,554,399.06 in the previous period[21]. - Cash inflow from investment activities totaled 158,682,963.50, down from 256,129,890.04 in the prior period[21]. - The net cash flow from financing activities was 42,617,203.44, recovering from a net outflow of -45,291,688.38 previously[22]. - The total cash and cash equivalents at the end of the period were 227,345,683.05, a decrease from 310,534,580.34 at the beginning of the period[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,407[10]. - The largest shareholder, Chen Jinzhan, holds 16,362,811 shares, representing 12.15% of total shares[10]. - There are no significant changes in the top 10 shareholders or their shareholding status due to securities lending activities[11]. Research and Development - The company's R&D investment totaled CNY 24,095,479.17, accounting for 9.02% of operating revenue, a decrease from 9.57% in the previous year[5]. - Research and development expenses for Q1 2025 were CNY 24,095,479.17, slightly down from CNY 24,845,984.25 in Q1 2024[18]. - The company has not reported any new product or technology developments in this period[12]. Inventory and Receivables - Accounts receivable increased from ¥548,138,774.34 to ¥569,331,118.55, an increase of about 3.9%[13]. - Inventory decreased from ¥104,361,324.22 to ¥82,726,864.24, a reduction of approximately 20.7%[13]. - Total current assets increased slightly from ¥1,435,698,565.84 to ¥1,444,213,864.32, an increase of about 0.6%[13].